Anti Interleukin-2 (IL2)

Determination of Peak Serum Levels and Immune Response to the Humanized Anti-Ganglioside Antibody-Interleukin-2 Immunocytokine

Tumor reactive monoclonal antibodies (mAb) have been developed and tested as anti-tumor therapy. Some mAb have shown efficacy and are now approved as clinical cancer therapy. The mechanism of action for the antitumor effect includes tumor

Development of Novel Major Histocompatibility Complex Class I and Class II-Deficient NOD-SCID IL2R Gamma Chain Knockout Mice for Modeling Human Xenoge

to result predominately from a human anti-mouse major histocompatibility complex (MHC) class II reactivity. Our recent development of NOD-scid IL2rγ null β2m null and NOD-scid IL2rγ null Ab null stocks of mice now make it possible to investigate

血管里的“斑块清洁工”来了！CD25+调节性T细胞变身CAR-Treg，效果惊人

于对机体免疫调节机制的了解，最终为相关疾病的治疗开辟新的免疫治疗途径。 为鼎力协助科研和药企人员针对IL-2RA（CD25）在多种免疫疾病和肿瘤中的临床应用研究，CUSABIO推出IL-2RA（CD25）活性蛋白（Code: CSB-MP011649HU3），助力您在IL-2RA（CD25）机制方面的研究或其潜在临床价值的探索。 ● IL-2RA（CD25）蛋白 Recombinant Human Interleukin-2 receptor subunit alpha(IL2RA),partial